



**ROME MAY 7/8, 2023**  
**SECOND INTERNATIONAL**  
**SUMMIT ON LUNG CANCER**

SCIENTIFIC COMMITTEE  
**FEDERICO CAPPUZZO - SILVIA NOVELLO**

SCIENTIFIC SECRETARIAT  
**LORENZA LANDI - GABRIELE MINUTI**

IN COLLABORATION WITH



UNDER THE AUSPICES OF



## SCIENTIFIC COMMITTEE

### FEDERICO CAPPUZZO

Oncology Department Director  
Istituto Nazionale Tumori "Regina Elena"  
Rome, Italy

### SILVIA NOVELLO

Professor of Medical Oncology  
Oncology Department AOU San Luigi  
University of Turin  
Italy

## SCIENTIFIC SECRETARIAT

### LORENZA LANDI

Head of the UOSD Clinical Trials: Phase 1 and Precision Medicine  
Istituto Nazionale Tumori "Regina Elena"  
Rome, Italy

### GABRIELE MINUTI

Physician of the Phase 1 UOSD and Precision Medicine  
Istituto Nazionale Tumori "Regina Elena"  
Rome, Italy

## DAY 1 | MAY 7, 2023

09.00 **Welcome by authorities**

09.10 Lecture **The evolving landscape of lung cancer** Giorgio V. Scagliotti

### PREVENTION AND EARLY DETECTION OF LUNG CANCER

Chairs: Lucio Crinò, Fred Hirsch

09.40 **Expert's opinion** Fred Hirsch

09.45 **Tobacco cessation among patients with lung cancer** April Plank

09.55 **Early detection of lung cancer** Ugo Pastorino

### 10.05 Panel Discussion

Lucio Crinò, Fred Hirsch, Ugo Pastorino, April Plank

### LIQUID BIOPSY AND NEW BIOMARKERS

Chairs: Jair Bar, Simonetta Buglioni, Giuseppe Perrone, Gabriella Sozzi

10.20 **Expert's opinion** Gabriella Sozzi

10.25 **Liquid biopsy for screening and early detection** Christian Rolfo

10.35 **Practical applications of liquid biopsy** Natasha Leighl

10.45 **Liquid biopsy for guiding therapy decision** Umberto Malapelle

10.55 **Neoantigen landscape and Tumor Mutational Burden** Patrick Alexander Ott

### 11.05 Panel Discussion

Jair Bar, Simonetta Buglioni, Natasha Leighl, Umberto Malapelle, Patrick Alexander Ott, Giuseppe Perrone, Christian Rolfo, Gabriella Sozzi

### NEOADJUVANT THERAPY OF LUNG CANCER

Chairs: Francesco Facciolo, Domenico Galetta, Francesco Grossi

11.20 **Expert's opinion** Francesco Grossi

11.25 **Chemoimmunotherapy in resectable NSCLC** Bartomeu Massuti

11.35 **PD-L1 expression and efficacy of neoadjuvant chemoimmunotherapy** Patrick Forde

11.45 **Neoadjuvant chemoimmunotherapy and tumor stage** Jonathan Spicer

11.55 **Post-surgery options** Nicolas Girard

12.05 **Role of MRD** Nicola Normanno

### 12.15 Panel Discussion

Francesco Facciolo, Patrick Forde, Domenico Galetta, Nicolas Girard, Francesco Grossi, Bartomeu Massuti, Nicola Normanno, Jonathan Spicer

12.30 Lunch



## ADJUVANT THERAPY

Chairs: Antonio D'Andrilli, Anne-Marie C. Dingemans, Simon Ekman, Giorgio V. Scagliotti, Piergiorgio Solli

13.20 **Expert's opinion** Anne-Marie C. Dingemans

13.25 **Anti-EGFR agents in the adjuvant setting** Yi-Long Wu

13.35 **Options for non-EGFR mutant/oncogene addicted resected NSCLC** Christian Grohe

13.45 **Adjuvant immunotherapy** Maurice Perol

13.55 **PD-L1 expression and choice of adjuvant immunotherapy** Enriqueta Felip Font

### 14.05 **Panel Discussion**

Antonio D'Andrilli, Anne-Marie C. Dingemans, Simon Ekman, Enriqueta Felip Font, Christian Grohe, Maurice Perol, Giorgio V. Scagliotti, Piergiorgio Solli, Yi-Long Wu

## INTEGRATED THERAPIES FOR STAGE III NSCLC

Chairs: Raffaele Califano, Alessandra Cancellieri, Andrea Filippi, Sara Ramella

14.20 **Expert's opinion** Sara Ramella

14.25 **Challenges in staging N2 disease** Rocco Trisolini

14.35 **Radiotherapy for N2 resected NSCLC** Cecile Le Pechoux

14.45 **Impact of neoadjuvant chemoimmunotherapy in management of stage III NSCLC** Marcello Tiseo

14.55 **Maintenance immunotherapy in stage III unresectable NSCLC** Umberto Ricardi

### 15.05 **Panel Discussion**

Raffaele Califano, Alessandra Cancellieri, Andrea Filippi, Cecile Le Pechoux, Sara Ramella, Umberto Ricardi, Marcello Tiseo, Rocco Trisolini

15.20 **Lecture Neoadjuvant immunotherapy in lung cancer** Tina Cascone

16.20 **Conclusion first day**

DAY 2  
MAY 8, 2023

## IMMUNOTHERAPY FOR FIRST-LINE NSCLC

Chairs: Lorenza Landi, Mariarita Migliorino, Rolf Stahel, H. Jack West

09.00 **Expert's opinion** Rolf Stahel

09.05 **Monoimmunotherapy for advanced NSCLC PD-L1 >50%:** Jair Bar

09.15 **Monoimmunotherapy or chemoimmunotherapy in PD-L1>50%** Solange Peters

09.25 **Immunotherapy options for squamous-cell lung cancer** Rafal Dziadziuszko

09.35 **Immunotherapy for unfit NSCLC** Siow Ming Lee

09.45 **Combination with anti-CTLA4** Luis Paz-Ares Rodríguez

09.55 **New immunotherapy combinations** Delvys Rodriguez-Abreu

10.05 **Immunotherapy combinations for KRAS G12C mutant NSCLC** Dolores Isla

### 10.15 **Panel Discussion**

Jair Bar, Rafal Dziadziuszko, Dolores Isla, Lorenza Landi, Mariarita Migliorino, Siow Ming Lee, Luis Paz-Ares Rodríguez, Solange Peters, Delvys Rodriguez-Abreu, Rolf Stahel, H. Jack West

## EMERGING OPTIONS IN IMMUNE-PRETREATED NSCLC

Chairs: Federico Cappuzzo, Keunchil Park, Francesco Passiglia

10.35 **Expert's opinion** Hossein Borghaei

10.40 **Mechanisms of resistance to immunotherapy** Paola Nisticò

10.50 **Novel strategies for overcoming resistance to checkpoint inhibitors**  
Naiyer Rizvi

11.00 **Targeting TAM receptors in immune-pretreated NSCLC** Ross Soo

11.10 **ADC in pretreated NSCLC** Federico Cappuzzo

### 11.20 **Panel Discussion**

Hossein Borghaei, Federico Cappuzzo, Paola Nisticò, Keunchil Park, Francesco Passiglia, Naiyer Rizvi, Ross Soo

## THE COLOSSEUM

Called by the ancient Romans, "Anphitheatrum Flavium" (Flavian Amphitheatre), the Colosseum is the most famous and impressive monument of ancient Rome, as well as the largest amphitheater in the world. The name is undoubtedly linked to the large size of the building but derives above all from the fact that nearby there was a colossal statue of Nero and bronze.

In 1990, the **Colosseum**, along with all the historical center of Rome, the Vatican extraterritorial zones in Italy and the Basilica of St. Paul Outside the Walls, was listed as a World Heritage Site by UNESCO, while in July 2007 was included among the New seven Wonders of the World..

## **BETWEEN IMMUNOTHERAPY AND TARGET THERAPY-ROLE OF KRAS**

Chairs: Mark M. Awad, Ruggero De Maria, Stephen Liu, Paolo Marchetti, Konstantinos Syrigos

11.35 **Expert's opinion** Stephen Liu

11.40 **KRAS and co-mutations. Impact of STK11 or KEAP1** Ferdinandos Skoulidis

11.50 **Agents targeting KRAS G12C** Silvia Novello

12.00 **KRAS inhibitors: Single agent or in combination?** Konstantinos Syrigos

12.10 **Emerging agents in KRAS mutated** Paolo Bironzo

### **12.20 Panel Discussion**

Mark M. Awad, Paolo Bironzo, Ruggero De Maria, Stephen Liu, Paolo Marchetti, Silvia Novello, Ferdinandos Skoulidis, Konstantinos Syrigos

12.35 Lunch

## **TARGETED THERAPIES FOR NSCLC**

Chairs: Benjamin Besse, Emilio Bria, Federico Cappuzzo, Jordi Remon Masip

13.35 **Expert's opinion** Federico Cappuzzo

13.40 **Standard options for EGFR mutant NSCLC** Pasi A. Janne

13.50 **EGFR inhibitors in combination with anti-angiogenic agents** Pilar Garrido

14.00 **Impact of p53 co-mutations on EGFR-TKI efficacy** Benjamin Besse

14.10 **Drugging exon 20 mutations** Rosario Garcia Campelo

14.20 **New drugs for HER2 deregulated NSCLC** Egbert Smit

14.30 **Options for BRAF mutant patients** David Planchard

14.40 **Options for MET exon 14 mutated patients** Jordi Remon Masip

14.50 **Best first-line agent for ALK + NSCLC** Sai-Hong Ignatius Ou

15.00 **Options for ROS1+ NSCLC** Lorenza Landi

15.10 **Options for NTRK rearranged tumors** Roberto Ferrara

15.20 **RET inhibitors in lung cancer** Rita Chiari

15.30 **NRG1: a new target in NSCLC** Gabriele Minuti

### **15.40 Panel Discussion**

Benjamin Besse, Emilio Bria, Federico Cappuzzo, Rita Chiari, Roberto Ferrara, Rosario Garcia Campelo, Pilar Garrido, Pasi A. Janne, Lorenza Landi, Gabriele Minuti, Sai-Hong Ignatius Ou, David Planchard, Jordi Remon Masip, Egbert Smit

## **SMALL CELL LUNG CANCER AND MESOTHELIOMA**

Chairs: Andrea Ardizzoni, Fabiana Cecere, Sara Pilotto

16.00 **Expert's opinion** Jordi Remon Masip

16.05 **Immunotherapy as first-line therapy in SCLC** Andrea Ardizzoni

16.15 **Immunotherapy combinations as first-line therapy in SCLC** Charles Rudin

16.25 **Immunotherapy for patients with pleural mesothelioma** Federica Grosso

### **16.35 Panel Discussion**

Andrea Ardizzoni, Fabiana Cecere, Federica Grosso, Sara Pilotto, Charles Rudin

16.50 Closing Lecture **Rediscovering IHC in lung cancer** Keith Kerr

17.20 **Closing remarks** Federico Cappuzzo

### **ST. PETER'S BASILICA**

The Papal Basilica of Saint Peter in the Vatican or simply Saint Peter's Basilica is a church built in the Renaissance style located in Vatican City, the papal enclave that is within the city of Rome. It was initially planned by Pope Nicholas V and then Pope Julius II to replace the aging Old St. Peter's Basilica, which was built in the 4th century by Roman emperor Constantine the Great. Construction of the present basilica began on 18 April 1506 and was completed on 18 November 1626. Designed principally by Donato Bramante, Michelangelo, Carlo Maderno and Gian Lorenzo Bernini, St. Peter's is the most renowned work of Renaissance architecture and the largest church in the world by interior measure.

**FACULTY**

**Andrea Ardizzoni**  
Bologna - I

**Mark M. Awad**  
Boston - US

**Jair Bar**  
Tel Aviv - IL

**Benjamin Besse**  
Paris- F

**Paolo Bironzo**  
Turin - I

**Hossein Borghaei**  
Philadelphia - US

**Emilio Bria**  
Rome - I

**Simonetta Buglioni**  
Rome - I

**Raffaele Califano**  
Manchester - UK

**Alessandra Cancellieri**  
Rome - I

**Federico Cappuzzo**  
Rome - I

**Tina Cascone**  
Houston - US

**Fabiana Letizia Cecere**  
Rome - I

**Rita Chiari**  
Pesaro - Fano - I

**Lucio Crinò**  
Meldola/Forlì - I

**Antonio D'Andrilli**  
Rome - I

**Ruggero De Maria**  
Rome - I

**Anne-Marie C. Dingemans**  
Maastricht -NL

**Rafal Dziadziuszko**  
Danzica - PL

**Simon Ekman**  
Uppsala - S

**Francesco Facciolo**  
Rome - I

**Enriqueta Felip Font**  
Barcelona - E

**Roberto Ferrara**  
Milan - I

**Andrea Riccardo Filippi**  
Pavia - I

**Patrick Forde**  
Baltimore - US

**Domenico Galetta**  
Bari - I

**Rosario Garcia Campelo**  
Coruña - E

**Pilar Garrido Lopez**  
Madrid - E

**Nicolas Girard**  
Paris- F

**Christian Grohe**  
Berlin - I

**Francesco Grossi**  
Varese - I

**Federica Grosso**  
Alessandria - I

**Fred Hirsch**  
New York - US

**Dolores Isla**  
Saragozza - E

**Pasi A. Janne**  
Boston - US

**Keith Kerr**  
Aberdeen - UK

**Lorenza Landi**  
Rome - I

**Cecile Le Pechoux**  
Paris- F

**Natasha Leighl**  
Toronto - CDN

**Stephen Liu**  
Georgetown - US

**Umberto Malapelle**  
Naples - I

**Paolo Marchetti**  
Rome - I

**Bartomeu Massuti**  
Alicante - E

**Maria Rita Migliorino**  
Rome - I

**Siow Ming Lee**  
London - UK

**Gabriele Minuti**  
Rome - I

**Paola Nisticò**  
Rome - I

**Nicola Normanno**  
Naples - I

**Silvia Novello**  
Turin - I

**Patrick Alexander Ott**  
Boston - US

**Sai-Hong Ignatius Ou**  
Orange - US

**Keunchil Park**  
Seoul - ROK

**Francesco Passiglia**  
Turin - I

**Ugo Pastorino**  
Milan - I

**Luis Paz-Ares Rodríguez**  
Madrid - E

**Maurice Perol**  
Lione - F

**Giuseppe Perrone**  
Rome - I

**Solange Peters**  
Lausanne - CH

**Sara Pilotto**  
Verona - I

**David Planchard**  
Villejuif - F

**April Plank**  
New York - US

**Sara Ramella**  
Rome - I

**Jordi Remon Masip**  
Paris- F

**Umberto Ricardi**  
Turin - I

**Naiyer Rizvi**  
San Francisco - US

**Delvys Rodriguez-Abreu**  
Gran Canaria - E

**Christian Rolfo**  
New York - US

**Charles Rudin**  
New York - US

**Giorgio Vittorio Scagliotti**  
Turin - I

**Ferdinandos Skoulidis**  
Houston - US

**Egber Smit**  
Leida - NL

**Piergiorgio Solli**  
Bologna - I

**Ross Soo**  
Singapore - MY

**Gabriella Sozzi**  
Milan - I

**Jonathan Spicer**  
Montreal Trudeau - CDN

**Rolf Stahel**  
Zurich - CH

**Marcello Tiseo**  
Parma - I

**Rocco Trisolini**  
Rome - I

**Howard Jack West**  
Duarte - US

**Yi-Long Wu**  
Guangdong - RC

## GENERAL INFORMATION

This event will take place only in person.

## VENUE

**Hotel Le Meridien Visconti Rome**

Via Federico Cesi, 37 Rome

## REGISTRATION

Registration is free of charge.

Please complete the process to register at our site [www.mitcongressi.it](http://www.mitcongressi.it)

Have a question about the upcoming conference?

Email: [segreteria@mitcongressi.it](mailto:segreteria@mitcongressi.it)

## 14 ECM FOR ITALIAN PARTICIPANTS ONLY

Medical specialties:

**Pharmacy**

**Biology**

**Biomedical Technician**

**Medical Radiology Technician**

**Medical Physic**

**Surgeon** Allergy and Immunology - Anatomic and Clinical Pathology - Anesthesiology - General Surgery - Thoracic Surgery - Palliative Medicine - Hospital Clinical management - Pharmacology and Medical Toxicology - Genetics - Pulmonary Disease - Internal Medicine - Nuclear Medicine - Oncology - Pathology - Radiation Oncology - Diagnostic Radiology

**Cardiocirculatory and Cardiovascular Perfusion Technitian**

**Nurse**

## CME INSTRUCTIONS

The CME Questionnaire and Certificate of Participation will be available online by accessing our platform in the "My courses" section of your reserved area. For the purpose of acquiring credits, you will need 90% in person attendance and a score of 75% or higher on the learning assessment questionnaire. You must have both in person attendance and questionnaire completion to obtain credit. The deadline for the completion of the ECM assessment questionnaire and the course approval questionnaire is set within 72 hours from the end of the course.

## ORGANIZATIONAL SUPPORT

Anna Maria Edilisca

## PROVIDER AND LOGISTIC SECRETARIAT



MI&T srl - Centro Direzionale Bolomnia Via Guelfa, 5 - 40138 Bologna

[info@mitcongressi.it](mailto:info@mitcongressi.it) - [www.mitcongressi.it](http://www.mitcongressi.it)

UNRESTRICTED GRANT BY

PLATINUM

AstraZeneca 

GOLD

 MSD

 NOVARTIS

SILVER

 BAYER

 Bristol Myers Squibb™

 Eisai  
 *Eisai*  Human Health Care

*Lilly*

OSE IMMUNO  
THERAPEUTICS 

 Pfizer  
Oncology

 Roche

sanofi  
REGENERON

ThermoFisher  
SCIENTIFIC

BRONZE

AMGEN®

 BeiGene

janssen  Oncology  
PHARMACEUTICAL COMPANY OF Schering-Plough

MIRATI  
THERAPEUTICS

Pharma  
Mar 